Pertinax Pharma has appointed Nigel Brooksby as chairman of the company. His main task will be the commercialisation of Pertinax, launched last month.
Nigel Brooksby, Former chairman of Sanofi, is an experienced businessman and entrepreneur in the life sciences arena. Out of his 38 year career in the pharmaceutical industry, over the last seven years, he has been involved as chairman, director and strategic adviser in raising significant investment.
Nigel Brooksby said: “I am delighted to take on this position at such a pivotal phase in the company’s development. Pertinax has enormous market potential in multiple fields. We are already in talks with several manufacturers and over the course of the next twelve months, we confidently expect to have applications of Pertinax in development for use in wound care, veterinary and dental products.”
Michele Barbour, Founder and CSO of Pertinax Pharma said: “We are delighted that Nigel has chosen to join our board. His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand. Indeed, we look forward to Nigel playing a pivotal role in Pertinax Pharma’s continued development as we bring the benefits of our patented and commercialised Pertinax technology to the healthcare sector.”